Benzinga | Feb 12, 2021 10:19AM EST

Citigroup Downgrades Alnylam Pharmaceuticals to Neutral, Raises Price Target to $175

Citigroup analyst Joel Beatty downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Neutral and raises the price target from $170 to $175.